Danske Bank A S Makes New Investment in Stryker Corporation $SYK

Danske Bank A S bought a new stake in Stryker Corporation (NYSE:SYK) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 208,386 shares of the medical technology company’s stock, valued at approximately $65,608,000. Danske Bank A S owned approximately 0.05% of Stryker at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of SYK. Diversify Advisory Services LLC purchased a new position in Stryker in the 2nd quarter valued at approximately $5,817,000. Gables Capital Management Inc. purchased a new stake in Stryker during the second quarter worth $25,000. Strategic Wealth Advisors LLC grew its holdings in Stryker by 50.4% in the second quarter. Strategic Wealth Advisors LLC now owns 197 shares of the medical technology company’s stock valued at $62,000 after purchasing an additional 66 shares during the last quarter. First National Bank of Omaha increased its position in shares of Stryker by 61.4% in the second quarter. First National Bank of Omaha now owns 8,129 shares of the medical technology company’s stock valued at $2,639,000 after buying an additional 3,092 shares in the last quarter. Finally, Navigoe LLC acquired a new position in shares of Stryker during the 2nd quarter worth $34,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently commented on SYK shares. Sanford C. Bernstein set a $410.00 price target on shares of Stryker in a research report on Friday, May 1st. Deutsche Bank Aktiengesellschaft set a $315.00 price objective on Stryker in a research report on Friday, May 1st. JPMorgan Chase & Co. reduced their target price on Stryker from $400.00 to $350.00 and set an “overweight” rating on the stock in a research note on Friday, July 31st. UBS Group started coverage on Stryker in a report on Tuesday, July 28th. They set a “buy” rating and a $400.00 target price on the stock. Finally, BTIG Research cut their price target on Stryker from $371.00 to $358.00 and set a “buy” rating for the company in a report on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, Stryker currently has a consensus rating of “Moderate Buy” and an average target price of $386.28.

Stryker Stock Up 0.1%

SYK opened at $331.96 on Wednesday. Stryker Corporation has a 12 month low of $281.00 and a 12 month high of $396.86. The business has a 50-day moving average of $325.56 and a two-hundred day moving average of $333.05. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33. The stock has a market capitalization of $127.33 billion, a price-to-earnings ratio of 34.40, a price-to-earnings-growth ratio of 2.16 and a beta of 0.76.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, topping the consensus estimate of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The business had revenue of $6.59 billion for the quarter, compared to analyst estimates of $6.58 billion. During the same period in the prior year, the firm posted $3.13 EPS. The company’s revenue was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, research analysts expect that Stryker Corporation will post 15.02 earnings per share for the current year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be paid a dividend of $0.88 per share. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. Stryker’s dividend payout ratio (DPR) is currently 36.48%.

Insider Buying and Selling at Stryker

In other Stryker news, insider Debra King sold 826 shares of Stryker stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total value of $277,783.80. Following the transaction, the insider owned 6,210 shares in the company, valued at $2,088,423. This trade represents a 11.74% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Ronda E. Stryker sold 310,000 shares of the business’s stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the sale, the director directly owned 1,924,880 shares of the company’s stock, valued at $601,005,282.40. This represents a 13.87% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 315,370 shares of company stock worth $98,463,501 in the last quarter. 4.60% of the stock is owned by insiders.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.